X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ELDER PHARMA SHASUN PHARMA/
ELDER PHARMA
 
P/E (TTM) x 123.9 -0.2 - View Chart
P/BV x 8.5 0.1 8,455.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ELDER PHARMA
Jun-14
SHASUN PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs94380 24.8%   
Low Rs46188 24.3%   
Sales per share (Unadj.) Rs214.2491.2 43.6%  
Earnings per share (Unadj.) Rs5.3-3.2 -167.7%  
Cash flow per share (Unadj.) Rs15.814.4 109.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3376.5 14.2%  
Shares outstanding (eoy) m56.6220.54 275.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.6 56.4%   
Avg P/E ratio x13.1-89.3 -14.7%  
P/CF ratio (eoy) x4.419.7 22.4%  
Price / Book Value ratio x1.30.8 173.7%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9585,833 67.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1642,179 99.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,12710,089 120.2%  
Other income Rs m229257 89.4%   
Total revenues Rs m12,35610,346 119.4%   
Gross profit Rs m1,009-792 -127.4%  
Depreciation Rs m594361 164.3%   
Interest Rs m4152,756 15.1%   
Profit before tax Rs m230-3,653 -6.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m-73125 -58.1%   
Profit after tax Rs m302-65 -462.3%  
Gross profit margin %8.3-7.8 -106.0%  
Effective tax rate %-31.7-3.4 924.1%   
Net profit margin %2.5-0.6 -384.6%  
BALANCE SHEET DATA
Current assets Rs m6,8849,240 74.5%   
Current liabilities Rs m8,4569,998 84.6%   
Net working cap to sales %-13.0-7.5 172.6%  
Current ratio x0.80.9 88.1%  
Inventory Days Days6246 133.1%  
Debtors Days Days10860 179.4%  
Net fixed assets Rs m4,97010,124 49.1%   
Share capital Rs m113206 55.1%   
"Free" reserves Rs m2,8755,582 51.5%   
Net worth Rs m3,0207,734 39.1%   
Long term debt Rs m1,8174,889 37.2%   
Total assets Rs m13,34722,882 58.3%  
Interest coverage x1.6-0.3 -477.5%   
Debt to equity ratio x0.60.6 95.2%  
Sales to assets ratio x0.90.4 206.1%   
Return on assets %5.411.8 45.7%  
Return on equity %10.0-0.8 -1,183.8%  
Return on capital %13.322.3 59.7%  
Exports to sales %46.43.0 1,525.4%   
Imports to sales %14.20.4 3,335.0%   
Exports (fob) Rs m5,622307 1,833.5%   
Imports (cif) Rs m1,72843 4,008.6%   
Fx inflow Rs m5,843307 1,905.6%   
Fx outflow Rs m2,173125 1,734.3%   
Net fx Rs m3,669181 2,024.0%   
CASH FLOW
From Operations Rs m39811,754 3.4%  
From Investments Rs m-1,635-561 291.7%  
From Financial Activity Rs m1,309-6,762 -19.4%  
Net Cashflow Rs m714,432 1.6%  

Share Holding

Indian Promoters % 39.2 39.6 99.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 7.5 48.0%  
FIIs % 17.6 16.8 104.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 36.1 109.7%  
Shareholders   20,750 16,479 125.9%  
Pledged promoter(s) holding % 12.3 77.6 15.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS